ALDX$4.41
$4.35
Chart
Performance
Key Stats
AI ALDX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldAldeyra Therapeutics (ALDX) shows some promising thematic aspects in its drug development pipeline, but its current financial and technical indicators suggest a speculative 'Hold' rating. The company is pre-revenue and has a history of net losses, with a volatile stock performance. Investors should closely monitor clinical trial results and regulatory approvals.
Thematic
Aldeyra Therapeutics operates in the biotechnology sector, focusing on immune-mediated and metabolic diseases. Its core product candidate, reproxalap, targets dry eye disease and allergic conjunctivitis, areas with significant market potential. However, the success of these therapies is heavily dependent on clinical trial outcomes and regulatory approvals, introducing substantial binary risk.
Fundamental
Aldeyra Therapeutics is a pre-revenue biotechnology company with a history of significant net losses and negative earnings per share. While it holds substantial cash reserves, its valuation metrics are not currently supported by revenue or profits. The company has minimal debt.
Technical
The stock price for Aldeyra Therapeutics has experienced significant volatility, reflecting its speculative nature. Current technical indicators suggest a period of consolidation or potential slight downside pressure, with mixed signals from oscillators and moving averages.
| Factor | Score |
|---|---|
| Biotechnology & Drug Development | 70 |
| Target Market Size | 75 |
| Regulatory Hurdles | 40 |
| Competition | 50 |
| Emerging Therapies | 70 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Valuation | 10 |
| Profitability | 10 |
| Profitability | 10 |
| Growth | 5 |
| Balance Sheet Health | 70 |
| Cash Flow | 20 |
| Cash Reserves | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Momentum | 60 |
| Volume Confirmation | 50 |
| Support & Resistance | 55 |
| Short-term Volatility | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive Short-Term Momentum
The stock has shown a strong positive performance over the last month (+36.28%) and year-to-date (-1.05%), indicating recent investor interest and potential for continued upward movement.
Mixed but Potentially Bullish Signals
While many short-term indicators (e.g., EMA 10, SMA 10, EMA 20, SMA 20) suggest a 'Sell', longer-term indicators (e.g., EMA 100, SMA 100, EMA 200, SMA 200) are mixed to 'Buy'. Oscillators like Stochastic %K and Williams Percent Range show 'Buy' signals, suggesting potential for price improvement, despite some short-term headwinds.
Bearish Points (7)
Consistent Net Losses and Negative EPS
The company has consistently reported net losses and negative Earnings Per Share (EPS) for the past several fiscal years and quarters (e.g., EPS TTm -0.97, Net Income 2024 -55.85M). This indicates a lack of current profitability, a significant risk for investors.
Unprofitable Company with No P/E Ratio
As the company is not currently profitable, a Price-to-Earnings (P/E) ratio is not applicable. The lack of positive earnings for valuation purposes increases the speculative nature of an investment.
Calendar
July 2025
31
Next Earnings Date
H: $-0.17
A: $-0.19
L: $-0.23
Profile
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Seasonals
Price Target
8.67 USD
The 39 analysts offering 1 year price forecasts for ALDX have a max estimate of 11.00 and a min estimate of 6.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Acquired Oyster Point Pharma (TYRVAYA for dry eye) and Kala Pharmaceuticals (EYSUVIS for dry eye flares), making them a very strong direct competitor with significant dry eye disease products.
Weight: 93
Major pharmaceutical company with a significant presence in the dry eye disease market through its acquisition of Allergan and its flagship product, Restasis.
Weight: 90
A leading global pharmaceutical company with a strong ophthalmology franchise, including Xiidra for dry eye disease, directly competing with ALDX's focus.
Weight: 89
Biotechnology company focused on ocular conditions, particularly Demodex blepharitis and dry eye disease, creating direct pipeline and market overlap.